VEGFA and interstitial lung disease: On the other hand, the OR of ILD incidence at grade ≥ 3 with VEGF/VEGFR inhibitors was 1.00 (95% CI, 0.43–2.36; p = 0.99), which did not represent a significant incidence compared to that without VEGF/VEGFR inhibitors (Figure 3B).